Jundishapur Journal of Microbiology

Published by: Kowsar

Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients

Yunus Gurbuz 1 , Baris Ozturk 2 , * , Emin Ediz Tutuncu 1 , Irfan Sencan 1 , Gonul Cicek Senturk 1 and Fatma Aybala Altay 1
Authors Information
1 Infectious Diseases and Clinical Microbiology Clinics, Diskapi Yildirim Beyazit Training and Research Hospital, Ministry of Health, Ankara, Turkey
2 Infectious Diseases and Clinical Microbiology Clinics, Ulucanlar Training and Research Hospital, Ministry of Health, Ankara, Turkey
Article information
  • Jundishapur Journal of Microbiology: October 01, 2015, 8 (10); e26514
  • Published Online: October 20, 2015
  • Article Type: Research Article
  • Received: January 7, 2015
  • Revised: May 20, 2015
  • Accepted: July 7, 2015
  • DOI: 10.5812/jjm.26514

To Cite: Gurbuz Y, Ozturk B, Tutuncu E E, Sencan I, Cicek Senturk G, et al. Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients, Jundishapur J Microbiol. 2015 ; 8(10):e26514. doi: 10.5812/jjm.26514.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis. 2004; 39(2): 284-7[DOI][PubMed]
  • 2. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents. 2010; 36 Suppl 1-6[DOI][PubMed]
  • 3. Whitehouse C. Crimean?Congo hemorrhagic fever. Antiviral Res. 2004; 64(3): 145-60[DOI]
  • 4. Gunes T, Poyraz O, Vatansever Z. Crimean-Congo hemorrhagic fever virus in ticks collected from humans, livestock, and picnic sites in the hyperendemic region of Turkey. Vector Borne Zoonotic Dis. 2011; 11(10): 1411-6[DOI][PubMed]
  • 5. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H, et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol. 2005; 54: 385-9[DOI][PubMed]
  • 6. Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006; 6(4): 203-14[DOI]
  • 7. Akinci E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis. 2013; 13(7): 429-37[DOI][PubMed]
  • 8. Weber F, Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev. 2008; 19(5-6): 395-404[DOI][PubMed]
  • 9. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis. 2006; 193(7): 941-4[DOI][PubMed]
  • 10. Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol. 2006; 36(4): 272-6[DOI][PubMed]
  • 11. Ozturk B, Kuscu F, Tutuncu E, Sencan I, Gurbuz Y, Tuzun H. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol. 2010; 47(2): 115-9[DOI][PubMed]
  • 12. Chuang YC, Lin YS, Liu CC, Liu HS, Liao SH, Shi MD, et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc. 2013; 112(1): 12-7[DOI][PubMed]
  • 13. Djamiatun K, Faradz SM, Setiati TE, Netea MG, van der Ven AJ, Dolmans WM. Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-b1 in children with dengue haemorrhagic fever in Indonesia. J Trop Pediatr. 2011; 57(6): 424-32[DOI][PubMed]
  • 14. Rachman A, Rinaldi I. Coagulopathy in dengue infection and the role of interleukin-6. Acta Med Indones. 2006; 38(2): 105-8[PubMed]
  • 15. Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009; 13(3): 380-6[DOI][PubMed]
  • 16. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989; 11 Suppl 4-800[PubMed]
  • 17. Bakir M, Gozel MG, Koksal I, Asik Z, Gunal O, Yilmaz H, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015; 34(2): 325-30[DOI][PubMed]
  • 18. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect. 2006; 12(6): 551-4[DOI][PubMed]
  • 19. Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug A, Kubar A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008; 12(4): 374-9[DOI][PubMed]
  • 20. Tasdelen Fisgin N, Tanyel E, Doganci L, Tulek N. Risk factors for fatality in patients with Crimean-Congo haemorrhagic fever. Trop Doct. 2009; 39(3): 158-60[DOI][PubMed]
  • 21. Ozturk B, Tutuncu E, Kuscu F, Gurbuz Y, Sencan I, Tuzun H. Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions. Int J Infect Dis. 2012; 16(2)-93[DOI][PubMed]
  • 22. Jiang Z, Tang X, Xiao R, Jiang L, Chen X. Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells. J Infect. 2007; 55(2)-8[DOI][PubMed]
  • 23. Huang Y, Liu C, Wang S, Lei H, Liu H, Lin Y, et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol. 2001; 63(3): 247-51[DOI]
  • 24. Shyu HW, Lin YY, Chen LC, Wang YF, Yeh TM, Su SJ, et al. The dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways. Thromb Haemost. 2010; 104(6): 1219-27[DOI][PubMed]
  • 25. Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007; [DOI]
  • 26. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, et al. Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome. Clin Infect Dis. 2002; 35(3): 277-85[DOI][PubMed]
  • 27. Heller MV, Marta RF, Sturk A, Maiztegui JI, Hack CE, Cate JW, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost. 1995; 73(3): 368-73[PubMed]
  • 28. Huang YH, Lei HY, Liu HS, Lin YS, Chen SH, Liu CC, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol. 2003; 70(4): 610-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments